Exhibitors Search
Inha University Research and Business Foundation
Booth no.
D52
| Exhibition | KOREA LIFE SCIENCE |
|---|---|
| Country | Korea, South |
| Address | 100 Inha-ro, Michuhol-gu, Incheon, Republic of Korea |
| Tel (Rep.) | 032-860-7245 |
| Website | http://rnd.inha.ac.kr |
Company Introduction
Since its establishment in 2004, Inha University’s Industry-Academic Cooperation Foundation has led technology transfer and commercialization. In the biohealth field, Inha University Hospital has been designated a Research-Centered Hospital and operates the Open Innovation Lab to maximize synergy between clinical practice and research. Through the RISE program, we connect regional and global companies as a hub for innovation. At this event, we present cutting-edge technologies including the Next-Generation Immunotherapy Platform, the c-Fos Inhibitory Peptide?Based Cancer Therapeutics Platform, and the LRG1 Protein for the Treatment of Diabetic Erectile Dysfunction, aiming to advance future medicine and global health.
Promotional video
Exhibit Item
Next-Gen Immunotherapy Platform, c-Fos Inhibitory Peptide?Based Cancer Therapeutics Platform, LRG1 Protein for the Treatment of Diabetic Erectile Dysfunction
Exhibit Item Images
-
Product Name : Next-Generation Immunotherapy PlatformA platform technology that chemically modifies natural polysaccharides to regulate immune responses in a desired direction. Oxidation, reduction, and acetylation modifications can enhance immunity, enabling applications in the treatment of cancer and infectious diseases. -
Product Name : LRG1 Protein for the Treatment of Diabetic Erectile DysfunctionA therapeutic candidate developed by modifying the LRG1 protein or removing its glycan components (deglycosylation) to maximize vascular and neural regeneration effects. Unlike conventional LRG1 glycoprotein mechanisms that rely on TGF-β signaling, this candidate binds to LPHN2, demonstrating strong efficacy in promoting vascular and neural regener -
Product Name : c-Fos Inhibitory Peptide?Based Cancer Therapeutics PlatformA peptide development technology that inhibits c-Fos, a protein that promotes cancer cell growth and resistance to anticancer drugs. The peptide works by disrupting the interaction between c-Fos and NQO1, a protein that stabilizes c-Fos in cancer cells, thereby destabilizing c-Fos. This mechanism leads to reduced cancer cell survival and increased
Exhibit Description
Co-Exhibitor or
Partner’s Information
| Company Name | Country |
|---|---|
KYUNGYON EXHIBITION CORP.